Sugi Predict

Sugi Predict / Compounds / SCHEMBL214913

SCHEMBL214913

SCHEMBL214913

Cc1cc(N2CCN(C(=O)OC(C)(C)C)CC2)ccc1N

nearest known ligand 0.60

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.60
▸ ALDH1A1 P00352 1/20 0.60
▸ LMNA P02545 1/20 0.60
▸ GPR119 Q8TDV5 8/20 0.53
▸ MEN1 O00255 3/20 0.52
▸ KMT2A Q03164 3/20 0.52
▸ SMN1; SMN2 Q16637 3/20 0.52
▸ PDK2 Q15119 1/20 0.52
▸ TSHR P16473 1/20 0.52
▸ GAA P10253 1/20 0.51
▸ RAD52 P43351 1/20 0.51
▸ CYP2C19 P33261 1/20 0.50
▸ SMARCA2 P51531 1/20 0.50
▸ SMARCA4 P51532 1/20 0.50
▸ PBRM1 Q86U86 1/20 0.50
▸ NAMPT P43490 1/20 0.49
▸ HTT P42858 1/20 0.47
▸ NPSR1 Q6W5P4 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29803690 1.00 MAPT (0.60) MAPTALDH1A1LMNAGPR119MEN1
SCHEMBL22652114 0.95 MAPT (0.55) MAPTALDH1A1LMNAGPR119MEN1
SCHEMBL31130013 0.90 MAPT (0.56) MAPTALDH1A1LMNAGPR119MEN1
SCHEMBL470199 0.90 MAPT (0.56) MAPTALDH1A1LMNAGPR119MEN1
SCHEMBL31130014 0.90 MAPT (0.56) MAPTALDH1A1LMNAGPR119MEN1
SCHEMBL30565931 0.89 MAPT (0.62) MAPTALDH1A1LMNAGPR119MEN1
SCHEMBL214944 0.89 MAPT (0.62) MAPTALDH1A1LMNAGPR119MEN1
SCHEMBL15863100 0.88 MAPT (0.58) MAPTALDH1A1LMNAGPR119MEN1
SCHEMBL25447362 0.88 MAPT (0.60) MAPTALDH1A1LMNAGPR119MEN1
SCHEMBL12331686 0.87 MAPT (0.56) MAPTALDH1A1LMNAGPR119MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4652161-A1 2,4-DIANILINOPYRIMIDINE-BASED AURORA-A KINASE SELECTIVE DEGRADATION INDUCING COMPOUNDS Uppthera, Inc. (KR) 2025-11-26 — — EP disclosed
US-20250018046-A1 COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS BIOGEN MA INC. 2025-01-16 — — US disclosed
WO-2024155112-A1 2,4-DIANILINOPYRIMIDINE-BASED AURORA-A KINASE SELECTIVE DEGRADATION INDUCING COMPOUNDS UPPTHERA, INC. (KR) 2024-07-25 — — WO disclosed
WO-2024141052-A1 ESTROGEN-RECEPTOR MODULATOR AND USE THEREOF 江苏威凯尔医药科技有限公司 2024-07-04 — — WO disclosed
CN-118271284-A Estrogen receptor modulators and uses thereof 江苏威凯尔医药科技有限公司 2024-07-02 — — CN disclosed
EP-4366834-A1 COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS Biogen MA Inc. (US) 2024-05-15 — — EP disclosed
CN-117957225-A Compounds for targeting degradation of IRAK4 proteins 渤健马萨诸塞州股份有限公司 2024-04-30 — — CN disclosed
EP-3966207-B1 PHENYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS LLC (US) 2023-11-01 — — EP disclosed
US-20230338376-A1 AMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS, LLC 2023-10-26 — — US disclosed
US-20230338376-A1 AMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS, LLC 2023-10-26 — — US disclosed
WO-2008042282-A2 IMIDAZOLE-4, 5-DICARBOXAMIDE DERIVATIVES AS JAK-2 MODULATORS EXELIXIS, INC. (US) 2008-04-10 — — WO disclosed
US-20070249620-A1 Urea Derivative SANKYO COMPANY, LIMITED (JP) 2007-10-25 — — US disclosed
US-7273863-B1 Benzophenones as inhibitors of reverse transcriptase SMITHKLINE BEECHAM CORPORATION (US) 2007-09-25 — — US disclosed
EP-1764360-A1 UREA DERIVATIVE Sankyo Company, Limited (JP) 2007-03-21 — — EP disclosed
US-6555541-B1 P2X7 receptor antagonists for treatment of inflammatory respiratory system disorders such as asthma; for example, 2-(3,4-Difluorophenylamino)-N-(2-methyl-5-piperazin-1-yl-methyl-phenyl) -acetamide, trihydrochloride ASTRAZENECA UK LIMITED (GB) 2003-04-29 — — US disclosed
US-6492355-B1 Adamantane derivatives ASTRAZENECA AB (SE) 2002-12-10 — — US disclosed
EP-1185522-A1 SUBSTITUTED PHENYL COMPOUNDS WITH IMMUNOSUPPRESSING ACTIVITY AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AstraZeneca AB (SE) 2002-03-13 — — EP disclosed
EP-1171432-A1 ADAMANTANE DERIVATIVES AstraZeneca AB (SE) 2002-01-16 — — EP disclosed
WO-2000071529-A1 SUBSTITUTED PHENYL COMPOUNDS WITH IMMUNOSUPPRESSING ACTIVITY AND PHARMACEUTICAL COMPOSITIONS ASTRAZENECA AB (SE) 2000-11-30 — — WO disclosed
WO-2000061569-A1 ADAMANTANE DERIVATIVES ASTRAZENECA AB (SE) 2000-10-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250018046-A1 COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS IRAK4, IRAK2, IRAK1 MAPT 764/4885ALDH1A1 2646/4885LMNA 1737/4885
US-20070249620-A1 Urea Derivative UGP2, SLC14A1, DGAT1 MAPT 758/4885ALDH1A1 731/4885LMNA 3721/4885
US-20230338376-A1 AMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF BECN1, SQSTM1, ATG7 MAPT 940/4885ALDH1A1 2251/4885LMNA 2982/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.